In brief
The controversy surrounding the inefficacy of generic drugs has led to widespread distrust among the Chinese populace, with healthcare professionals voicing concerns that the government's procurement policies favor cheaper medications at the expense of safety. Experts and citizens alike are calling for improved quality control and better access to original medications amidst the discussions.
Public anger has surged in China recently over growing concerns about the effectiveness of generic medications prescribed in public hospitals. Doctors have voiced their worries that the country’s drug procurement system, which prioritizes cheap generics over higher-quality brand-name drugs, is compromising patient safety. In response to these mounting fears, government officials have downplayed the allegations, suggesting that perceptions of ineffectiveness stem largely from anecdotal reports rather than concrete evidence.The scrutiny began in December, following the announcement of contracts awarded to nearly 200 domestic drug manufacturers to supply China's public hospitals. Medical practitioners such as Zheng Minhua from Shanghai have brought attention to troubling instances, including antibiotics that fail to alleviate conditions and laxatives that do not work effectively. Zheng’s concerns quickly went viral on social media, where users shared similar experiences, raising alarms over the public’s trust in hospital-provided medications.Despite government assurances that generics adhere to required standards, citizens have expressed skepticism and are increasingly purchasing brand-name alternatives independently. Recent posts on social media reveal that many people are hesitant to use generic drugs, often opting for original formulations based solely on perceived efficacy and experience.The root of the problem lies in the government’s 2018 procurement policy aimed at reducing healthcare costs. This system allows local governments to contract for roughly 70% of the state’s annual medicine requirements, favoring generic products that are primarily manufactured domestically. This has led to fears that the extreme price-cutting adopted by winning bidders compromises medication quality, with one bid reportedly offering aspirin for less than one cent.Concerns have also been raised over potential data manipulation regarding drug efficacy trials, with reports indicating that some generic medications may lack proper independent testing, further muddying public perceptions. As China faces a rapidly aging population and soaring healthcare demands, the pressure on its medical system has intensified. Ongoing protests and dissatisfaction with insufficient healthcare coverage have led to a crisis in public trust towards medical providers.In light of the escalating controversy, the National Healthcare Security Administration has acknowledged the issue and stated that improvements to the procurement process are necessary to reinforce safety. However, as public confidence wanes, people are left wondering whether the measures taken will genuinely safeguard their health or simply perpetuate a cycle of distrust in the medical system.
